RYZOLT by Purdue Pharma is ). Approved for moderate to moderately severe chronic pain in adults. First approved in 2008.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
RYZOLT is an extended-release oral tablet containing tramadol, a centrally acting analgesic that works through monoamine reuptake inhibition and weak opioid receptor agonism. It is indicated for moderate to moderately severe chronic pain in adults. The drug is formulated as a racemate with dose-proportional pharmacokinetics across the 100-300 mg range.
As LOE approaches, the brand team faces revenue decline and potential downsizing; focus shifts to life-cycle management and cost control rather than growth initiatives.
). RYZOLT™ is formulated as a racemate and both tramadol and M1 are detected in the circulation. The pharmacokinetics of tramadol and M1 are dose-proportional over a 100 to 300 mg dose range in healthy subjects. ). and ). The total amount of tramadol and M1 removed during a 4-hour dialysis period…
Worked on RYZOLT at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on RYZOLT offers limited growth opportunity given the product's LOE-approaching status and lack of active pipeline support. This role is best suited for professionals seeking stability in a mature product environment or gaining experience in life-cycle management and generic transition planning.